Published in Br J Pharmacol on May 01, 1981
Evaluation of sex differences in cannabinoid dependence. Drug Alcohol Depend (2014) 0.84
Increased platelet membrane [3H]-LSD binding in patients on chronic neuroleptic treatment. Br J Clin Pharmacol (1985) 0.75
Protein measurement with the Folin phenol reagent. J Biol Chem (1951) 1743.91
Studies in vivo on the relationship between brain tryptophan, brain 5-HT synthesis and hyperactivity in rats treated with a monoamine oxidase inhibitor and L-tryptophan. J Neurochem (1971) 3.34
Serotonergic component of neuroleptic receptors. Nature (1978) 1.74
Behavioral evidence for the rapid release of CNS serotonin by PCA and fenfluramine. Eur J Pharmacol (1976) 1.66
[Modification of the cerebral serotonin level in the rat by trifluoromethyl-2-phenyl ethyl aminopropane (Fenfluramine 768 S)]. Arch Int Pharmacodyn Ther (1967) 1.37
"Wet-dog" shake behaviour in the rat: a possible quantitative model of central 5-hydroxytryptamine activity. Neuropharmacology (1977) 1.24
Striatal dopamine receptors become supersensitive while rats are geven trifluoperazine for six months. Nature (1979) 1.14
High-affinity binding of (3H) 5-hydroxytryptamine to brain synaptosomal membranes: comparison with (3H) lysergic acid diethylamide binding. Mol Pharmacol (1978) 0.99
Effect of drugs on the tryptamine content of rat tissues. J Pharmacol Exp Ther (1973) 0.97
3H-Spiroperidol labels serotonin receptors in rat cerebral cortex and hippocampus. Eur J Pharmacol (1978) 0.95
Changes in dopamine-mediated behaviour during one year's neuroleptic administration. Eur J Pharmacol (1979) 0.87
Backward walking and circling: behavioural responses induced by drug treatments which cause simultaneous release of catecholamines and 5-hydroxytryptamine. Br J Pharmacol (1979) 0.85
The effect of some putative neurotransmitters on the release of 5-hydroxytryptamine and gamma-aminobutyric acid from slices of the rat midbrain raphe area. Neuroscience (1979) 0.85
Similarities between the pharmacological actions of quipazine and serotonin. Eur J Pharmacol (1969) 0.84
A controlled study of tryptophan-benserazide in schizophrenia. Commun Psychopharmacol (1978) 0.81
Changes in rat striatal dopamine turnover and receptor activity during one years neuroleptic administration. Eur J Pharmacol (1980) 0.80
Comparative action of fenfluramine on the uptake and release of serotonin and dopamine. Eur J Pharmacol (1976) 0.79
Increased in vivo binding of 3H-pimozide in mouse striatum following repeated administration of haloperidol. Life Sci (1978) 0.78
The effects of quipazine on serotonin metabolism in rat brain. Life Sci (1976) 0.78
Butyrophenones and brain serotonin metaboism. Pol J Pharmacol Pharm (1976) 0.78
Chronic blockade of dopamine receptors by antischizophrenic drugs enhances GABA binding in substantia nigra. Nature (1980) 0.78
Effects of drugs acting on cerebral 5-hydroxytryptamine mechanisms on dopamine-dependent turning behaviour in mice. Br J Pharmacol (1976) 1.34
Circling behaviour produced by unilateral lesions in the region of the locus coeruleus in rats. Brain Res (1975) 1.31
Effect of lesion of cortical dopamine terminals on subcortical dopamine receptors in rats. Nature (1980) 1.31
"Wet-dog" shake behaviour in the rat: a possible quantitative model of central 5-hydroxytryptamine activity. Neuropharmacology (1977) 1.24
Specific stimulating effect of glycine on 3H-dopamine efflux from substantia nigra slices of the rat. Eur J Pharmacol (1979) 1.24
Effects of medicaid managed care on adults. Med Care (2000) 1.21
Galanin regulates the postnatal survival of a subset of basal forebrain cholinergic neurons. Proc Natl Acad Sci U S A (2000) 1.17
Coronary artery infusion of neuropeptide Y in patients with angina pectoris. Lancet (1987) 1.16
Focal contralateral myoclonus produced by inhibition of GABA action in the caudate nucleus of rats. Brain (1978) 1.16
Turning behaviour in animals. Neuroscience (1980) 1.13
Specificity in Trk receptor:neurotrophin interactions: the crystal structure of TrkB-d5 in complex with neurotrophin-4/5. Structure (2001) 1.11
Circling behaviour produced by asymmetric medial raphé nuclei lesions in rats. J Pharm Pharmacol (1976) 1.10
Time course and nerve growth factor dependence of inflammation-induced alterations in electrophysiological membrane properties in nociceptive primary afferent neurons. J Neurosci (2001) 1.09
Characterisation of ultraviolet-B-induced inflammation as a model of hyperalgesia in the rat. Pain (2007) 1.09
The status of glycine as a supraspinal neurotransmitter. Life Sci (1981) 1.04
Serotoninergic modulation of the dopamine response from the nucleus accumbens. J Pharm Pharmacol (1976) 1.00
Dopamine neurones of the ventral tegmentum project to both medial and lateral habenula. Some implications for habenular function. Exp Brain Res (1982) 1.00
Effect of 6-hydroxydopamine lesions of the medial prefrontal cortex on neurotransmitter systems in subcortical sites in the rat. J Neurochem (1980) 0.99
The rotating rodent: a two component system? Eur J Pharmacol (1978) 0.98
Profound and selective loss of catalytic TrkB immunoreactivity in Alzheimer's disease. Biochem Biophys Res Commun (1999) 0.96
Behavioural and biochemical effects of dopamine and noradrenaline depletion within the medial prefrontal cortex of the rat. Brain Res (1980) 0.96
Production of 2,3-butylene glycol from citrus wastes. II. The Bacillus polymyxa fermentation. Appl Microbiol (1965) 0.96
Studies on the role of catecholamines in the frontal cortex [proceedings]. Br J Pharmacol (1978) 0.96
A dopamine-5-hydroxytryptamine link in the hypothalamic pathways which mediate heat loss in the rat. J Physiol (1980) 0.94
The effects of bretylium on the subcellular distribution of noradrenaline and on adrenergic nerve function in rat heart. Br J Pharmacol (1973) 0.92
Sequestration of brain derived nerve factor by intravenous delivery of TrkB-Ig2 reduces bladder overactivity and noxious input in animals with chronic cystitis. Neuroscience (2010) 0.90
Survival of basal ganglia neuropeptide Y-somatostatin neurones in Huntington's disease. Brain Res (1985) 0.90
Astroglial response in the excitotoxically lesioned neostriatum and its projection areas in the rat. Neuroscience (1987) 0.88
The pharmacokinetics and sputum penetration of ampicillin and amoxycillin following simultaneous i.v. administration. J Antimicrob Chemother (1990) 0.88
Central deopaminergic receptor supersensitivity and its relevance to Parkinson's disease. J Neurol Sci (1977) 0.87
The validity of mitochondrial marker enzymes in rat heart. J Mol Cell Cardiol (1971) 0.87
Differential effects of central serotonin manipulation on hyperactive and stereotyped behaviour. Life Sci (1978) 0.86
Intranigral injection of capsaicin enhances motor activity and depletes nigral 5-hydroxytryptamine but not substance P. Neuropharmacology (1981) 0.86
Nerve growth factor receptor mRNA distribution in human brain: normal levels in basal forebrain in Alzheimer's disease. Brain Res Mol Brain Res (1989) 0.86
Antipsychotic drugs classified by their effects on the release of dopamine and noradrenaline in the prefrontal cortex and striatum. Eur J Pharmacol (2001) 0.86
Identification of syntaxin 1A as a novel binding protein for presenilin-1. Brain Res Mol Brain Res (2000) 0.86
Reduced cholinergic function in normal and Alzheimer's disease brain is associated with apolipoprotein E4 genotype. Neurosci Lett (1997) 0.86
Stereotyped behaviour patterns and hyperactivity induced by amphetamine and apomorphine after discrete 6-hydroxydopamine lesions of extrapyramidal and mesolimbic nuclei. Brain Res (1977) 0.85
The effect of centrally acting myorelaxants on NMDA receptor-mediated synaptic transmission in the immature rat spinal cord in vitro. Br J Pharmacol (1992) 0.85
Immunoreactivity to calcitonin gene-related peptide in the superior olivary complex and cochlea of cat and rat. Hear Res (1987) 0.85
The effect of some putative neurotransmitters on the release of 5-hydroxytryptamine and gamma-aminobutyric acid from slices of the rat midbrain raphe area. Neuroscience (1979) 0.85
Potentiation of synaptic reflexes by D-serine in the rat spinal cord in vitro. Eur J Pharmacol (1991) 0.85
Retinal neurotransmission. Surv Ophthalmol (1985) 0.84
Antipsychotic drugs induce similar effects on the release of dopamine and noradrenaline in the medial prefrontal cortex of the rat brain. Eur J Pharmacol (1998) 0.84
Possible GABA-mediated control of dopamine-dependent behavioural effects from the nucleus accumbens of the rat. Psychopharmacology (Berl) (1976) 0.84
A comparison of the effects of GABA and glycine on the release of [3H]-dopamine from rat striatal slices [proceedings]. Br J Pharmacol (1979) 0.84
Immunoglobulin-like domains define the nerve growth factor binding site of the TrkA receptor. Nat Biotechnol (1997) 0.84
Cloning of a non-catalytic form of human trkB and distribution of messenger RNA for trkB in human brain. Neuroscience (1994) 0.83
Primary afferent depolarization in the rat spinal cord is mediated by pathways utilising NMDA and non-NMDA receptors. Neurosci Lett (1989) 0.83
The effects of 5,7-dihydroxytryptamine lesions of extrapyramidal and mesolimbic sites on spontaneous motor behaviour, and amphetamine-induced stereotypy. Naunyn Schmiedebergs Arch Pharmacol (1979) 0.83
Commercial health plan participation in Medicaid managed care: an examination of six markets. Inquiry (2001) 0.83
Neurotensin attenuates the quinpirole-induced inhibition of the firing rate of dopamine neurons in the rat substantia nigra pars compacta and the ventral tegmental area. Neuroscience (2000) 0.82
A study of the sites of interaction between dopamine and 5-hydroxytryptamine for the production of fluphenazine-induced catalepsy. Naunyn Schmiedebergs Arch Pharmacol (1978) 0.82
Vasoactive intestinal polypeptide (VIP)-sensitive adenylate cyclase in rat brain: regional distribution and localization on hypothalamic neurons. J Pharm Pharmacol (1980) 0.82
Thalamic control of dopaminergic functions in the caudate-putamen of the rat--III. The effects of lesions in the parafascicular-intralaminar nuclei on D2 dopamine receptors and high affinity dopamine uptake. Neuroscience (1986) 0.82
Morphometric immunochemical analysis of neurons in the nucleus basalis of Meynert in Alzheimer's disease. Brain Res (1988) 0.81
Tyramine-induced noradrenaline release from rat brain slices: prevention by (-)-deprenyl. Br J Pharmacol (1983) 0.81
Recombinant human nerve growth factor for clinical trials: protein expression, purification, stability and characterisation of binding to infusion pumps. J Biochem Biophys Methods (2001) 0.81
Acute motor effects of N-methyl-D-aspartic acid and kainic acid applied focally to mesencephalic dopamine cell body regions in the rat. Neurosci Lett (1980) 0.81
Brain-derived neurotrophic factor, acting at the spinal cord level, participates in bladder hyperactivity and referred pain during chronic bladder inflammation. Neuroscience (2013) 0.81
The effects of pentobarbital and benzodiazepines on GABA-responses in the periphery and spinal cord in vitro. Neurosci Lett (1991) 0.81
Neural grafting in a rat model of Huntington's disease: striosomal-like organization of striatal grafts as revealed by acetylcholinesterase histochemistry, immunocytochemistry and receptor autoradiography. Neuroscience (1987) 0.81
Identification and structure of the nerve growth factor binding site on TrkA. Biochem Biophys Res Commun (2001) 0.81
Interactions of 5-hydroxytryptamine and gamma-aminobutyric acid with dopamine. Adv Biochem Psychopharmacol (1978) 0.80
In vitro modulation of the firing rate of dopamine neurons in the rat substantia nigra pars compacta and the ventral tegmental area by antipsychotic drugs. Neuropharmacology (2001) 0.80
New 1-aryl-4-(biarylmethylene)piperazines as potential atypical antipsychotics sharing dopamine D(2)-receptor and serotonin 5-HT(1A)-receptor affinities. Bioorg Med Chem Lett (2001) 0.79
Decreased somatostatin immunoreactivity but not neuropeptide Y immunoreactivity in cerebral cortex in senile dementia of Alzheimer type. Neurosci Lett (1986) 0.79
Studies on the interaction between cerebral 5-hydroxytryptamine and gamma-aminobutyric acid in the mode of action of diazepam in the rat. Br J Pharmacol (1983) 0.79
Normal beta-NGF content in Alzheimer's disease cerebral cortex and hippocampus. Neurosci Lett (1991) 0.78
Low affinity nerve growth factor receptor binding in normal and Alzheimer's disease basal forebrain. Neurosci Lett (1991) 0.78
An investigation into the interaction between ethanol at low doses and the benzodiazepines nitrazepam and temazepam on psychomotor performance in normal subjects. Psychopharmacology (Berl) (1983) 0.78
Cloning and characterization of the presenilin-2 gene promoter. Brain Res Mol Brain Res (1998) 0.78
Neuropeptide Y: regional distribution chromatographic characterization and immunohistochemical demonstration in post-mortem human brain. Brain Res (1984) 0.78
Thyrotrophin releasing hormone stimulates release of [3H]-dopamine from slices of rat nucleus accumbens in vitro. Br J Pharmacol (1979) 0.78
Behavioural and biochemical changes following chronic administration of L-dopa to rats. Eur J Pharmacol (1982) 0.78
The interaction of clonidine with dopamine-dependent behaviour in rodents. Naunyn Schmiedebergs Arch Pharmacol (1977) 0.77
Neuropeptides and dementia. Prog Brain Res (1986) 0.77
Potassium-stimulated release of radiolabelled taurine and glycine from the isolated rat retina. J Neurochem (1982) 0.77
Interactions of dopamine and the release of [3H]-taurine and [3H]-glycine from the isolated retina of the rat. Br J Pharmacol (1983) 0.76
Dopamine-dependent hyperactivity in the rat following manipulation of GABA mechanisms in the region of the nucleus accumbens. J Neural Transm (1979) 0.76
Evidence that thalamic efferent neurones are non-cholinergic: a study in the rat with special reference to the thalamostriatal pathway. Brain Res (1984) 0.76
The role of 5-hydroxytryptamine in dopamine-dependent stereotyped behaviour. Neuropharmacology (1981) 0.76
Inhibition of turning behaviour by clozapine in mice with unilateral destruction of dopaminergic nerve terminals. J Pharm Pharmacol (1975) 0.76
Distribution of beta-nerve growth factor receptors in the human basal forebrain. J Comp Neurol (1989) 0.76
Possible importance of 5-hydroxytryptamine in neuroleptic-induced catalepsy in rats [proceedings]. Br J Pharmacol (1977) 0.76
Lesions of the frontal cortex of the rat: changes in neurotransmitter systems in sub-cortical regions [proceedings]. Br J Pharmacol (1978) 0.75
Lesions of the superior colliculus in the rat differentiate between nigrostriatal and mesolimbic dopamine systems. Brain Res (1982) 0.75
Evidence in vitro for a 5-HT link in dopaminergic neurotransmission in the anterior hypothalamic region of the rat: demonstration of a 5-HT link in dopaminergic thermoregulation? [proceedings]. Br J Pharmacol (1980) 0.75
Chronic amphetamine administration and central dopamine receptor sensitivity [proceedings]. Br J Pharmacol (1977) 0.75
Interaction of clonidine with dopamine-dependent behaviours in rodents [proceedings]. Br J Pharmacol (1976) 0.75
Interactions of putative neurotransmitters in the region of the raphé nuclei of the rat [proceedings]. Br J Pharmacol (1979) 0.75
Behavioural and biochemical studies in rats with N-methyl-D-aspartic acid and kainic acid [proceedings]. Br J Pharmacol (1980) 0.75
Evidence in vivo for a 5-hydroxytryptamine link in dopamine-receptor-mediated hypothermia in the rat [proceedings]. Br J Pharmacol (1980) 0.75
A comparison of stereospecificity at central and peripheral 'muscarine-sensitive' acetylcholine receptors: observations with the enantiomeric forms of procyclidine and tricyclamol. Br J Pharmacol (1981) 0.75
The effect of bretylium on endogenous and newly-synthesized noradrenaline in the microsomal fraction of rat heart. Br J Pharmacol (1974) 0.75
Proceedings: Differences in circling responses following electrolytic and 6-hydroxydopamine lesions of the nigro-striatal pathway. Br J Pharmacol (1975) 0.75